Research Comparison
Retatrutide (LY3437943) vs Semaglutide
A side-by-side research comparison of Retatrutide (LY3437943) and Semaglutide drawn from Cobalt Peptides' peptide database records.
Retatrutide (LY3437943)
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist with activity at the GLP-1, GIP and glucagon receptors. Its design combines incretin-axis signalling through GLP-1 and GIP with glucagon receptor activity, a combination studied for its effects on energy balance in published metabolic research. Retatrutide is not an approved medicine in the United Kingdom or elsewhere and remains in clinical development by its originator. Supplied strictly as a research compound for laboratory use.
Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is acylated with a C18 fatty diacid through a γ-glutamyl spacer, which promotes albumin binding and extends its half-life to approximately seven days. The published literature describes GLP-1 receptor activation with downstream effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing semaglutide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.